Gliomark

New Diagnostics for Gliomas

Navigation
announcement

GLIOMARK1 clinical study successfully completed

The GLIOMARK consortium is delighted to announce that the Gliomark1 Phase II clinical study has been successfully completed.

Gliomark1: Phase II exploratory study assessing the technical performance of 99mTc-tetrofosmin for the differentiation of tumour recurrence vs. radiation-necrosis in patients with high grade brain tumours following initial treatment (EudraCT No.: 2015-005573-21, ClinicalTrials.gov ID: NCT02971319).

The study, conducted in 6 large glioma centers in Europe, met all end-points, regarding both technical and diagnostic performance of 99mTc-tetrofosmin, and sets a strong basis for the design of a successful phase III confirmatory study.

The Consortium wishes to thank all the Principal Investigators and their dedicated teams, as well as our highly experienced team of Medical Advisors for their impactful contribution and commitment to bringing the study to its successful completion.

Dr Alex Strongilos, CEO of proACTINA, stated that “the successful completion of the phase II study is a major advancement towards the completion of this ambitious project and it constitutes a very strong foundation for the upcoming Phase III study”.

Dr Daniel Schubart, Managing Director of ConsulTech, stated that “We have now reached a very important milestone of the GLIOMARK project and we are very enthusiastic about this significant achievement”.

Meet us at BioEUROPE in Cologne

The consortium will participate in Europe's largest partnering conference serving the global biotechnology industry, the BIO-Europe.
You may approach us through the partnering system of the conference. We look forward to discussing cooperations with you.

Orphan designation for Tetrofosmin

The consortium is pleased to announce that, on 14/10/2016 the European Commission has granted to proACTINA SA, Orphan Designation for tetrofosmin for the diagnosis of Glioma, following positive opinion by EMA. The product is registered in the “Community register of orphan medicinal products” with an EU orphan designation number: EU/3/16/1764.

This achievement has been one of the major milestones in GLIOMARK project.

See here the related press release.